TY  - JOUR
T1  - A CASE OF CHICKENPOX INFECTION FOLLOWING COVID-19 VACCINATION
TT  - A CASE OF CHICKENPOX INFECTION FOLLOWING COVID-19 VACCINATION
AU  - Durusu, İrem Nur
AU  - Gurel, Gulhan
PY  - 2025
DA  - January
Y2  - 2022
DO  - 10.18229/kocatepetip.1132844
JF  - Kocatepe Tıp Dergisi
JO  - KTD
PB  - Afyonkarahisar Sağlık Bilimleri Üniversitesi
WT  - DergiPark
SN  - 3061-9904
SP  - 76
EP  - 79
VL  - 26
IS  - 1
LA  - en
AB  - We are in the middle of Coronavirus disease 2019 (COVID-19) pandemic and to take control the disease burden several COVID-19 vaccines have been authorized and approved for distribution worldwide. Pfizer-BioNTech vaccine which is a nucleoside-modified RNA vaccine (BNT162b2 Comirnatry) is one of the most important and effective COVID-19 vaccines. As the number of vaccinated people increases, we see various cutaneous side effects related to vaccination. Delayed local reactions, morbilliform rashes, urticaria are among the most common side effects. Herein, a 38-year-old immunocompetent patient with second time experienced chickenpox infection developed immediately after the second dose of Pfizer-BioNTech vaccine is presented. With this case, we reviewed the fact that chickenpox disease is not supply a life-long immunity in all people, it can be re-triggered by some immune mechanisms related with vaccination.
KW  - Chickenpox
KW  - SARS-CoV-2
KW  - COVID-19 Vaccines
N2  - Coronavirus hastalığı 2019 (COVID-19) pandemisinin ortasındayız ve hastalık yükünü kontrol altına almak için birçok COVID-19 aşısı dünya çapında dağıtım için yetkilendirildi ve onaylandı. Nükleozid modifiyeli bir RNA aşısı (BNT162b2 Comirnatry) olan Pfizer-BioNTech aşısı, en önemli ve etkili COVID-19 aşılarından biridir. Aşılanan kişi sayısı arttıkça aşıya bağlı çeşitli deri yan etkileri görülmektedir. Gecikmiş lokal reaksiyonlar, morbiliform döküntüler, ürtiker en sık görülen yan etkilerdir. Bu olguda, ikinci doz Pfizer-BioNTech aşısının hemen ardından gelişen, ikinci kez suçiçeği enfeksiyonu geçiren, immünitesi sağlam 38 yaşında bir hasta sunulmaktadır. Bu olgu ile suçiçeği hastalığının tüm insanlarda yaşam boyu bağışıklık sağlamadığını, aşıya bağlı bazı bağışıklık mekanizmaları tarafından yeniden tetiklenebileceğini gözden geçirdik.
CR  - 1. Katsikas Triantafyllidis K, Giannos P, Mian IT, et al. Varicella Zoster Virus Reactivation Following COVID-19 Vaccination: A Systematic Review of Case Reports. Vaccines 2021;9(9):1013.
79
CR  - 2. Sun Q, Fathy R, McMahon DE, Freeman EE. COVID-19 Vaccines and the Skin: The Landscape of Cutaneous 
Vaccine Reactions Worldwide. Dermatol Clin. 2021;39(4):653-73.
CR  - 3. Santovito LS, Pinna G. A case of reactivation of varicella–zoster virus after BNT162b2 vaccine second 
dose? Inflammation Research. 2021;70(9):935-7.
CR  - 4. Galván-Casas C, Català A, Muñoz-Santos C. SARS-CoV-2 Vaccines and the Skin. Actas Dermo-
Sifiliográficas. 2021;112(9):828-36.
CR  - 5. Gershon AA, Breuer J, Cohen JI, et al. Varicella zoster virus infection. Nature reviews Disease Primers. 
2015;1:1-18.
CR  - 6. Nastro F, Fabbrocini G, di Vico F, Marasca C. Small vessel vasculitis related to varicella‐zoster virus after 
Pfizer‐BioNTech COVID‐19 vaccine. Journal of the European Academy of Dermatology and Venereology. 
2021;35(11):e745-e7.
CR  - 7. Lladó I, Fernández-Bernáldez A, Rodríguez-Jiménez P. Varicella zoster virus reactivation and mRNA 
vaccines as a trigger. JAAD Case Reports. 2021;15:62-3.
CR  - 8. Nanova K, Zlotogorski A, Ramot Y. Recurrent varicella following SARS‐CoV‐2 vaccination with BNT162b2. 
International Journal of Dermatology. 2021;60(9):1148-9.
CR  - 9. Aksu SB, Öztürk GZ. A rare case of shingles after COVID-19 vaccine: is it a possible adverse effect? Clinical 
and Experimental Vaccine Research. 2021;10(2):198-201.
UR  - https://doi.org/10.18229/kocatepetip.1132844
L1  - http://dergipark.org.tr/tr/download/article-file/2495136
ER  -